Qube Research & Technologies Ltd trimmed its position in Boston Scientific Co. (NYSE:BSX) by 44.1% during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 3,245 shares of the medical equipment provider’s stock after selling 2,559 shares during the period. Qube Research & Technologies Ltd’s holdings in Boston Scientific were worth $106,000 at the end of the most recent quarter.

Other large investors have also recently made changes to their positions in the company. Captrust Financial Advisors increased its stake in Boston Scientific by 103.8% during the 2nd quarter. Captrust Financial Advisors now owns 3,129 shares of the medical equipment provider’s stock worth $102,000 after purchasing an additional 1,594 shares in the last quarter. Quad Cities Investment Group LLC bought a new stake in Boston Scientific during the 2nd quarter worth approximately $104,000. Kaizen Advisory LLC increased its stake in Boston Scientific by 146.7% during the 2nd quarter. Kaizen Advisory LLC now owns 3,299 shares of the medical equipment provider’s stock worth $108,000 after purchasing an additional 1,962 shares in the last quarter. NumerixS Investment Technologies Inc increased its stake in Boston Scientific by 1,650.0% during the 2nd quarter. NumerixS Investment Technologies Inc now owns 3,500 shares of the medical equipment provider’s stock worth $114,000 after purchasing an additional 3,300 shares in the last quarter. Finally, Sun Life Financial INC increased its stake in Boston Scientific by 2,086.5% during the 2nd quarter. Sun Life Financial INC now owns 3,739 shares of the medical equipment provider’s stock worth $122,000 after purchasing an additional 3,568 shares in the last quarter. Institutional investors and hedge funds own 90.90% of the company’s stock.

In other news, EVP David A. Pierce sold 5,000 shares of the stock in a transaction that occurred on Monday, July 2nd. The stock was sold at an average price of $32.42, for a total value of $162,100.00. Following the completion of the sale, the executive vice president now owns 29,201 shares of the company’s stock, valued at approximately $946,696.42. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Also, Chairman Michael F. Mahoney sold 116,666 shares of the firm’s stock in a transaction on Monday, September 10th. The shares were sold at an average price of $35.88, for a total value of $4,185,976.08. Following the sale, the chairman now directly owns 2,023,104 shares of the company’s stock, valued at approximately $72,588,971.52. The disclosure for this sale can be found here. In the last three months, insiders sold 175,250 shares of company stock valued at $6,196,995. 0.73% of the stock is currently owned by insiders.

A number of research firms recently issued reports on BSX. Stifel Nicolaus reissued a “buy” rating and set a $37.00 target price on shares of Boston Scientific in a research note on Thursday, July 26th. Guggenheim reissued a “buy” rating and set a $43.00 target price on shares of Boston Scientific in a research note on Friday, July 27th. Jefferies Financial Group reissued a “hold” rating and set a $34.00 target price on shares of Boston Scientific in a research note on Thursday, July 26th. Sanford C. Bernstein began coverage on Boston Scientific in a research note on Wednesday, June 27th. They set an “outperform” rating and a $38.00 target price for the company. Finally, Argus increased their target price on Boston Scientific to $41.00 and gave the stock a “buy” rating in a research note on Wednesday, September 5th. They noted that the move was a valuation call. One research analyst has rated the stock with a sell rating, two have assigned a hold rating, nineteen have assigned a buy rating and three have assigned a strong buy rating to the company’s stock. The stock has an average rating of “Buy” and a consensus target price of $36.43.

NYSE BSX opened at $37.49 on Thursday. The company has a market capitalization of $52.03 billion, a PE ratio of 29.75, a P/E/G ratio of 2.62 and a beta of 0.63. The company has a debt-to-equity ratio of 0.62, a current ratio of 0.83 and a quick ratio of 0.60. Boston Scientific Co. has a 12 month low of $24.54 and a 12 month high of $37.76.

Boston Scientific (NYSE:BSX) last released its quarterly earnings data on Wednesday, July 25th. The medical equipment provider reported $0.41 EPS for the quarter, beating the consensus estimate of $0.34 by $0.07. The company had revenue of $2.49 billion during the quarter, compared to the consensus estimate of $2.47 billion. Boston Scientific had a return on equity of 26.35% and a net margin of 5.48%. The firm’s revenue for the quarter was up 10.3% compared to the same quarter last year. During the same quarter in the prior year, the firm posted $0.32 EPS. sell-side analysts forecast that Boston Scientific Co. will post 1.39 earnings per share for the current year.

Boston Scientific Profile

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through three segments: Cardiovascular, Rhythm Management, and MedSurg. The company offers interventional cardiology products, including drug-eluting coronary stent systems used in the treatment of coronary artery disease; percutaneous coronary interventions therapy products to treat atherosclerosis; intravascular catheter-directed ultrasound imaging catheters, fractional flow reserve devices, and systems for use in coronary arteries and heart chambers, as well as certain peripheral vessels; and structural heart therapy systems.

Read More: What is the Dow Jones Industrial Average (DJIA)?

Want to see what other hedge funds are holding BSX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Boston Scientific Co. (NYSE:BSX).

Institutional Ownership by Quarter for Boston Scientific (NYSE:BSX)

Receive News & Ratings for Boston Scientific Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Boston Scientific and related companies with MarketBeat.com's FREE daily email newsletter.